Pathogenesis of fatty liver diseases and hepatocellular carcinoma

Chiang, John Y.L.; Li, Tiangang

doi:10.1016/j.livres.2022.12.001

Cited by 1 publication

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Open access incidence worldwide, including in the USA. [5][6][7] Although the pathogenesis of liver cancer varies depending on potential aetiologies, the typical sequence involves liver injury, chronic inflammation, fibrosis, cirrhosis and liver cancer. 8 Cirrhosis, found in 80%-90% of patients with liver cancer, is the primary risk factor.…”

Section: Strengths and Limitations Of This Studymentioning

confidence: 99%

Modular multimodal hospital-home chain physical activity rehabilitation programme (3M2H-PARP) in liver cancer: a protocol for a randomised controlled trial

Chen,

Lu,

Zhou

et al. 2024

BMJ Open

View full text Add to dashboard Cite

IntroductionPatients with liver cancer are susceptible to experiencing a decline in muscle mass and function, which can lead to physical frailty and have a negative impact on prognosis. However, there is currently a lack of physical activity interventions specifically tailored for these patients. Therefore, we have developed a modular multimodal hospital-home chain physical activity rehabilitation programme (3M2H-PARP) designed specifically for patients with liver cancer undergoing transarterial chemoembolisation (TACE). We aim to validate the effectiveness and feasibility of this programme through a randomised controlled trial (RCT).Methods and analysis3M2H-PARP RCT will compare a 12-week, modular, multimodal physical activity rehabilitation programme that includes supervised exercise in a hospital setting and self-management exercise at home. The programmes consist of aerobic, resistance, flexibility and balance exercise modules, and standard survivorship care in a cohort of liver cancer survivors who have undergone TACE. The control group will receive standard care. A total of 152 participants will be randomly assigned to either the 3M2H-PARP group or the control group. Assessments will be conducted at three time points: baseline, after completing the intervention and a 24-week follow-up visit. The following variables will be evaluated: liver frailty index, Functional Assessment of Cancer Therapy-Hepatobiliary subscale, Cancer Fatigue Scale, Pittsburgh Sleep Quality Index, Hospital Anxiety and Depression Scale and physical activity level. After the completion of the training programme, semi-structured interviews will be conducted with participants from the 3M2H-PARP group to investigate the programme’s impact on their overall well-being. SPSS V.26.0 software will be used for statistical analyses.Ethics and disseminationEthical approval has been granted by the Jiangnan University School of Medicine Research Ethics Committee. The findings will be disseminated through publication in a peer-reviewed journal.Trial registration numberChiCTR2300076800.

show abstract